MedicalResearch.com: What are the main findings of the study?
Dr. Dunleavy: We found that low-intensity therapy was highly effective in Burkitt’s lymphoma and cured over 95% of patients with the disease.
MedicalResearch.com: Were any of the findings unexpected?
Dr. Dunleavy: Burkitt’s lymphoma is typically treated with very intensive chemotherapy regimens so the fact that it can be successfully treated with low-intensity therapy represents a paradigm shift.
MedicalResearch.com: What should clinicians and patients take away from your report?
Dr. Dunleavy: Low-intensity therapy (EPOCH-R based treatment) is highly effective in Burkitt’s lymphoma and associated with low toxicity compared to standard Burkitt’s lymphoma regimens.
MedicalResearch.com: What recommendations do you have for future research as a result of this study?
Dr. Dunleavy: To validate these results, we are currently studying this approach in a multi center study of Burkitt’s lymphoma and the approach is also being tested in a pediatric study.
Kieron Dunleavy, M.D., Stefania Pittaluga, M.D., Ph.D., Margaret Shovlin, R.N., Seth M. Steinberg, Ph.D., Diane Cole, M.S., Cliona Grant, M.D., Brigitte Widemann, M.D., Louis M. Staudt, M.D., Ph.D., Elaine S. Jaffe, M.D., Richard F. Little, M.D., and Wyndham H. Wilson, M.D., Ph.D.